๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Recombinant newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits

โœ Scribed by Lalita Ambigai Sivasamugham; Mary Jane Cardosa; Wen Siang Tan; Khatijah Yusoff


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
240 KB
Volume
78
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

โœฆ Synopsis


The complete VP1 protein of EV71 was truncated into six segments and fused to the C-terminal ends of full-length nucleocapsid protein (NPfl) and truncated NP (NPt; lacks 20% amino acid residues from its C-terminal end) of newcastle disease virus (NDV). Western blot analysis using anti-VP1 rabbit serum showed that the N-terminal region of the VP1 protein contains a major antigenic region. The recombinant proteins carrying the truncated VP1 protein, VP1(1-100), were expressed most efficiently in Escherichia coli as determined by Western blot analysis. Electron microscopic analysis of the purified recombinant protein, NPt-VP(1-100) revealed that it predominantly self-assembled into intact ring-like structures whereas NPfl-VP(1-100) recombinant proteins showed disrupted ring-like formations. Rabbits immunized with the purified NPt-VP(1-100) and NPfl-VP(1-100) exhibited a strong immune response against the complete VP1 protein. The antisera of these recombinant proteins also reacted positively with authentic enterovirus 71 and the closely related Coxsackievirus A16 when analyzed by an immunofluorescence assay suggesting their potential as immunological reagents for the detection of anti-enterovirus 71 antibodies in serum samples.


๐Ÿ“œ SIMILAR VOLUMES


Partial protection against enterovirus 7
โœ Wei-Choong Ch'ng; Eric J. Stanbridge; Kien-Chai Ong; Kum-Thong Wong; Khatijah Yu ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 627 KB

## Abstract Enterovirus 71 (EV71) infection may cause severe neurological complications, particularly in young children. Despite the risks, there are still no commercially available EV71 vaccines. Hence, a candidate vaccine construct, containing recombinant Newcastle disease virus capsids that disp